Coronary disease & ACSRandomised controlled trial

Timing of Complete Multivessel Revascularization in Acute Coronary Syndrome

JACC Cardiovasc IntervPublished

  • Randomised controlled trial
  • non-inferiority
  • multicentre (29 sites in Europe)
  • 2-year follow-up

Authors' conclusion

In patients with ACS and multivessel disease, there was no significant difference between immediate complete revascularization and staged complete revascularization with respect to the composite outcome of all-cause mortality, myocardial infarction, any unplanned ischemia-driven revascularization, and cerebrovascular event at 2 years.

Study context

Population
Patients with acute coronary syndromes (ACS) and multivessel coronary diseasefollow-up complete 97.6%
Participants
764 vs 761
Comparison
Immediate vs staged complete revascularization
  • Immediate complete revascularizationn = 764
  • Staged complete revascularizationn = 761reference
Primary endpoint
Composite of:
  • All-cause mortality
  • MI
  • Any unplanned ischemia-driven revascularization
  • Cerebrovascular event
Follow-up
2 years

Primary result

As reported in the abstract

Hazard ratio

0.98

95% CI 0.73–1.30

P = 0.88

By group

Immediate complete revascularization vs Staged complete revascularization
HR 0.98 (95% CI 0.73–1.30); P = 0.88

Further findings

OutcomeImmediate complete revascularizationStaged complete revascularizationHR (95% CI)P value
MI · 2 years3.8%6.2%0.60 (0.37–0.96)P = 0.032
All-cause mortality · 2 years3.3%2.0%1.67 (0.88–3.16)P = 0.12
Any unplanned ischemia-driven revascularization · 2 years7.0%7.9%0.87 (0.60–1.26)P = 0.57
Cerebrovascular event · 2 years2.5%1.7%1.39 (0.68–2.83)P = 0.37

Original publication

Timing of Complete Multivessel Revascularization in Acute Coronary Syndrome. JACC Cardiovasc Interv. Published 23 December 2024. doi:10.1016/j.jcin.2024.09.058

Summarised from the published abstract; every number is checked against it